kantor flydende middel
agroplanta gmbh & co. kg - additiv - flydende middel - 1000 g/l additiv
power oil flydende middel
adama northern europe b.v. - mineralsk, penetreringsolie - flydende middel - 1000 g/l mineralsk penetreringsolie ; (~ 1.000 g/l penetreringsolie
bravo 500 flydende middel
syngenta nordics a/s - chlorothalonil - flydende middel - 500 g/l chlorothalonil
aviator xpro emulsionskoncentrat
bayer a/s - prothioconazol, bixafen - emulsionskoncentrat - 150 g/l prothioconazol; 75 g/l bixafen
holoxan 500 mg pulver til injektions-/infusionsvæske, opløsning
baxter a/s - ifosfamid - pulver til injektions-/infusionsvæske, opløsning - 500 mg
grasustek
juta pharma gmbh - pegfilgrastim - neutropeni - immunostimulants, - reduktion i varigheden af neutropeni og forekomst af febril neutropeni hos voksne patienter behandlet med cytotoksisk kemoterapi for malignitet (med undtagelse af kronisk myeloid leukæmi og myelodysplastisk syndromer).
pirimor 500 wg vanddispergerbart granulat
adama northern europe b.v. - pirimicarb - vanddispergerbart granulat - 500 g/kg pirimicarb
riltrava aerosphere
astrazeneca ab - budesonide, formoterol fumarate dihydrate, glycopyrronium bromide - pulmonal sygdom, kronisk obstruktiv - medicin for obstruktiv sygdomme, - riltrava aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2 agonist or combination of a long-acting beta2 agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.
zolsketil pegylated liposomal
accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.